go-v.orgdoi

Niban apoptosis regulator 1 promotes gemcitabine resistance by activating the focal adhesion kinase signaling pathway in bladder cancer

Shiyu Tong, Hongling Yin, Jun Fu, Yangle Li · Journal of Cancer · 2022

  • DOI 10.7150/jca.66248
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2022

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2022

Abstract

Although intravesical gemcitabine (GEM) chemotherapy (IGC) can effectively reduce the recurrence risk of non-muscle invasive bladder cancer (NMIBC), the development of GEM resistance may occur and result in cancer recurrence and disease progression.Herein, a label-free proteomics approach was used to characterize the proteomic profiles of primary/post-IGC recurrent NMIBC.A total of 218 proteins were found to be differentially expressed in paired primary and post-IGC recurrent NMIBC.Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that multiple signaling pathways including "focal adhesion" were highly enriched in recurrent NMIBC.Niban apoptosis regulator 1 (NIBAN1) was identified as the top upregulated protein in recurrent NMIBC.Highly increased NIBAN1 expression was observed in a number of GEM-resistant cancer cell lines and in post-IGC recurrent NMIBC specimens.Manipulation of NIBAN1 expression affected the chemosensitivity to GEM in bladder cancer cell models.Moreover, NIBAN1 also regulated focal adhesion/focal adhesion kinase (FAK) signaling activation in bladder cancer cell lines.Highly elevated FAK (pY397) expression was observed in post-IGC recurrent NMIBC specimens, which was positively correlated with NIBAN1 expression.Knockdown of FAK markedly attenuated GEM resistance in GEM-resistant bladder cancer cells.In vivo studies demonstrated that knockdown of NIBAN1 disrupted FAK signaling and sensitized GEM-resistant bladder cancer cells to GEM treatment.Our findings suggest that NIBAN1 might regulate FAK signaling activation to promote GEM resistance in bladder cancer.Targeting NIBAN1/FAK signaling may help sensitize bladder cancer cells to GEM treatment.

Open the resolved locator · 10.7150/jca.66248

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:01 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v13p1103.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.